Use of CCL1 in therapy
A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
1. A method of treating multiple sclerosis (MS) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CCL1 fusion polypeptide comprising SEQ NO: 8 and an Fc constant region of an immunoglobulin, causing an increase in the activity of FOX P3 T regulatory cells (Tregs) and thereby suppression of effector T cells, thereby treating the MS in a subject in need thereof.
2. The method of claim 1 , wherein said CCL1 fusion polypeptide is as set forth in SEQ ID NO: 10.